Advertisement

Immunovant, Inc. IMVT

Set alert

Price alert · IMVT

All alert types
29.17 USD -0.47 -1.59%

At close · Oct 30

29.17 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
29.13 × 2
Ask
29.17 × 2
28.76 Day range 29.78
22.02 52-week range 44.96
YTD
+14.75%
1 year
+17.53%
Open
29.49
Prev close
29.64
Mkt cap
6.03B
Vol
1.17M
Avg vol
1.35M
EPS
-2.82
P/E
0.00
Div yield
0.00%
More statistics
Low
28.76
High
29.78
Forward P/E
-10.61
Beta
0.84
Short ratio
10.91
Inst. own
54.75%
Dividend
0.00
Ex-div date
Earnings
Nov 9, 2026
50-d avg
34.86
200-d avg
32.03
1y target
48.88

MAX chart

Chart tools
Interval

Events in this range
  • Aug 11, 2025Earnings: -0.6; estimate -0.69; surprise 13.04%
  • Nov 10, 2025Earnings: -0.73; estimate -0.72; surprise -1.39%
  • Feb 6, 2026Earnings: -0.61; estimate -0.72; surprise 15.28%
  • May 20, 2026Earnings: -0.73; estimate -0.59202; surprise -23.31%
  • May 21, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • May 21, 2026Rating: B of A Securities · Buy → Buy
  • May 22, 2026Rating: Truist Securities · Hold → Hold
  • May 26, 2026Rating: Guggenheim · Buy → Buy
  • Jun 30, 2026Rating: Citigroup · Buy → Buy
  • Aug 4, 2026Rating: JP Morgan · Overweight → Overweight
  • Aug 6, 2026Earnings: -0.75; estimate -0.6289; surprise -19.26%
Signals (116)
NameDateAgo
SMA: BearishSep 21, 20261 month ago
MACD: Sell SignalSep 7, 20261 month ago
SMA: BearishAug 31, 20262 months ago
RSI: OverboughtAug 10, 20262 months ago
RSI: OverboughtJun 22, 20264 months ago
MACD: Buy SignalMay 4, 20266 months ago
SMA: BullishApr 13, 20266 months ago
SMA: BearishMar 9, 20267 months ago
MACD: Sell SignalMar 2, 20268 months ago
SMA: BullishFeb 16, 20268 months ago
SMA: BearishFeb 9, 20268 months ago
RSI: OverboughtOct 27, 20251 year ago
SMA: BullishSep 22, 20251 year ago
SMA: BullishSep 22, 20251 year ago
SMA: BearishSep 8, 20251 year ago
SMA: BearishSep 8, 20251 year ago
SMA: BullishSep 1, 20251 year ago
SMA: BullishSep 1, 20251 year ago
SMA: BearishJul 28, 20251 year ago
SMA: BullishJun 2, 20251 year ago
MACD: Buy SignalJun 2, 20251 year ago
RSI: OversoldMay 5, 20251 year ago
RSI: OversoldMar 24, 20251 year ago
SMA: BearishNov 11, 20241 year ago
SMA: BearishNov 11, 20241 year ago
MACD: Sell SignalNov 11, 20241 year ago
SMA: BullishNov 4, 20241 year ago
SMA: BearishOct 7, 20242 years ago
SMA: BullishSep 30, 20242 years ago
SMA: BullishSep 30, 20242 years ago
SMA: BearishSep 9, 20242 years ago
SMA: BearishSep 9, 20242 years ago
SMA: BullishAug 19, 20242 years ago
MACD: Buy SignalJul 15, 20242 years ago
SMA: BullishJul 8, 20242 years ago
SMA: BearishMay 20, 20242 years ago
SMA: BullishMay 13, 20242 years ago
SMA: BearishMar 4, 20242 years ago
SMA: BearishJan 22, 20242 years ago
MACD: Sell SignalJan 22, 20242 years ago
RSI: OverboughtJan 1, 20242 years ago
RSI: OverboughtDec 11, 20232 years ago
SMA: BullishNov 27, 20232 years ago
RSI: OverboughtNov 27, 20232 years ago
SMA: BearishNov 20, 20232 years ago
SMA: BullishSep 25, 20233 years ago
MACD: Buy SignalSep 25, 20233 years ago
RSI: OverboughtSep 25, 20233 years ago
SMA: BearishSep 11, 20233 years ago
MACD: Sell SignalSep 11, 20233 years ago
MACD: Buy SignalSep 4, 20233 years ago
SMA: BullishAug 28, 20233 years ago
SMA: BearishAug 14, 20233 years ago
MACD: Sell SignalAug 14, 20233 years ago
MACD: Buy SignalJul 17, 20233 years ago
SMA: BullishJul 10, 20233 years ago
SMA: BearishJun 26, 20233 years ago
MACD: Sell SignalJun 26, 20233 years ago
MACD: Buy SignalMay 15, 20233 years ago
RSI: OverboughtMay 15, 20233 years ago
SMA: BullishApr 24, 20233 years ago
SMA: BullishApr 17, 20233 years ago
SMA: BearishApr 10, 20233 years ago
SMA: BearishFeb 20, 20233 years ago
MACD: Sell SignalFeb 20, 20233 years ago
RSI: OverboughtOct 3, 20224 years ago
SMA: BullishSep 26, 20224 years ago
SMA: BearishSep 5, 20224 years ago
SMA: BullishAug 8, 20224 years ago
SMA: BullishJul 4, 20224 years ago
SMA: BearishJun 27, 20224 years ago
SMA: BullishJun 20, 20224 years ago
RSI: OversoldJun 6, 20224 years ago
RSI: OversoldApr 18, 20224 years ago
SMA: BearishMar 21, 20224 years ago
SMA: BullishMar 14, 20224 years ago
RSI: OversoldJan 31, 20224 years ago
RSI: OversoldJan 17, 20224 years ago
SMA: BearishJan 3, 20224 years ago
SMA: BullishDec 27, 20214 years ago
SMA: BearishOct 18, 20215 years ago
SMA: BullishSep 27, 20215 years ago
RSI: OversoldJun 28, 20215 years ago
MACD: Buy SignalJun 21, 20215 years ago
RSI: OversoldMay 31, 20215 years ago
SMA: BearishMay 10, 20215 years ago
SMA: BullishMay 3, 20215 years ago
RSI: OversoldMar 22, 20215 years ago
RSI: OversoldFeb 15, 20215 years ago
SMA: BearishJan 25, 20215 years ago
SMA: BearishJan 11, 20215 years ago
SMA: BullishJan 4, 20215 years ago
SMA: BearishDec 28, 20205 years ago
MACD: Sell SignalDec 28, 20205 years ago
RSI: OverboughtDec 14, 20205 years ago
RSI: OverboughtSep 28, 20206 years ago
RSI: OverboughtAug 17, 20206 years ago
MACD: Buy SignalAug 10, 20206 years ago
SMA: BullishAug 3, 20206 years ago
MACD: Sell SignalJul 27, 20206 years ago
SMA: BearishJul 20, 20206 years ago
RSI: OverboughtJun 15, 20206 years ago
RSI: OverboughtMay 25, 20206 years ago
MACD: Buy SignalApr 20, 20206 years ago
SMA: BullishApr 6, 20206 years ago
SMA: BullishMar 23, 20206 years ago
SMA: BearishMar 16, 20206 years ago
SMA: BearishMar 9, 20206 years ago
MACD: Sell SignalMar 9, 20206 years ago
SMA: BullishMar 2, 20206 years ago
RSI: OverboughtMar 2, 20206 years ago
SMA: BearishFeb 10, 20206 years ago
SMA: BullishDec 9, 20196 years ago
RSI: OverboughtDec 9, 20196 years ago
SMA: BearishDec 2, 20196 years ago
RSI: OverboughtNov 18, 20196 years ago

Key statistics

Market cap
6.03B
Enterprise value
5.32B
Trailing P/E
0.00
Forward P/E
-10.61
PEG ratio
0.00
Price / sales
0.00
Price / book
8.18
EPS (TTM)
-2.82
Beta
0.84
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-238.70M
Total cash
797.80M
Total debt
0
Return on equity
-80.10%
Shares outstanding
206.55M
Short % of float
19.67%
50-day average
34.86
200-day average
32.03

Analyst view

Consensus: none

Price target (mean) 48.88 +67.6% upside
Target (low)
30.00
Target (mean)
48.88
Target (high)
66.00
Ratings (0m) 17 13 buy · 4 hold · 0 sell
  • Strong buy2
  • Buy11
  • Hold4
  • Sell0
  • Strong sell0

Next earnings

Nov 9, 2026

Expected Nov 9, 2026. Consensus EPS estimate -0.72212.

Earnings history

Financials — quick view

All financials
IMVT Revenue — quarterly 0
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
IMVT Net income — quarterly -153.22M
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
IMVT EPS — quarterly -0.75
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026

Earnings

IMVT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 9, 2026Sep 30, 2026-0.73701———
Aug 6, 2026Jun 30, 2026-0.6289-0.75-0.12-19.26%
May 20, 2026Mar 31, 2026-0.59202-0.73-0.14-23.31%
Feb 6, 2026Dec 31, 2025-0.72-0.61+0.11+15.28%
Nov 10, 2025Sep 30, 2025-0.72-0.73-0.01-1.39%
Aug 11, 2025Jun 30, 2025-0.69-0.60+0.09+13.04%

Upgrades / downgrades

IMVT analyst upgrades and downgrades
DateFirmActionFromTo
Aug 4, 2026JP MorganmainOverweightOverweight
Jun 30, 2026CitigroupmainBuyBuy
May 26, 2026GuggenheimmainBuyBuy
May 22, 2026Truist SecuritiesmainHoldHold
May 21, 2026B of A SecuritiesmainBuyBuy
May 21, 2026HC Wainwright & Co.mainBuyBuy

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on IMVT — it syncs with the Stock Master app.

Insider holders

IMVT insider holders
InsiderRelationLatest transactionDateShares held
BARNETT EVA RENEEChief Financial OfficerSaleApr 15, 2025396,774
GEFFNER MICHAELOfficerSaleOct 21, 2025217,958
GIRÃO TIAGO MChief Financial OfficerSaleJul 22, 2026240,798
GLORIA MELANIEChief Operating OfficerSaleAug 19, 2026219,301
LEVINE MARK SOfficerSaleNov 19, 2024319,228
MACIAS WILLIAM LOfficerSaleFeb 18, 2025357,353

Institution ownership

IMVT institution ownership
Holder% heldSharesValueReported
FMR, LLC7.84%16,186,469472.16MJun 29, 2026
Deep Track Capital, Lp4.52%9,341,151272.48MJun 29, 2026
Blackrock Inc.3.48%7,180,897209.47MJun 29, 2026
Farallon Capital Management LLC2.81%5,805,000169.33MJun 29, 2026
Baker Bros. Advisors, LP2.63%5,435,220158.55MJun 29, 2026
State Street Corporation2.24%4,617,005134.68MJun 29, 2026

Fund ownership

IMVT fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.47%5,092,337148.54MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.26%2,600,08675.84MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.09%2,251,14865.67MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.02%2,107,16361.47MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund0.91%1,881,79854.89MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund0.68%1,408,87241.10MAug 30, 2026
Advertisement